Press Releases Bristol-Myers Squibb Company

Equities

BMY

US1101221083

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 15:39:48 16/01/2026 GMT			5-day change	1st Jan Change
56.11 ^USD	-0.90%		+0.44%	+4.01%

01-13	Leerink Partners Adjusts Price Target on Bristol-Myers Squibb to $60 From $54, Maintains Outperform Rating	MT
01-12	Bristol Myers Squibb Announces Positive Topline Results from Phase 3 SCOUT-HCM Trial Evaluating Camzyos in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy	CI

Press Releases

01-12	Bristol Myers Squibb Announces Positive Topline Results from Phase 3 SCOUT-HCM Trial Evaluating Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)	BU
01-06	Bristol Myers Squibb : Preliminary Q4 2025 Acquired IPRD & Licensing Income	PU
01-02	Bristol Myers Squibb to Present at J.P. Morgan’s 44th Annual Healthcare Conference	BU
12-19	Bristol Myers Squibb Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans	BU
12-18	Bristol Myers Squibb to Report Results for Fourth Quarter 2025 on February 5, 2026	BU
12-11	U.S. Food and Drug Administration (FDA) Grants Priority Review to Bristol Myers Squibb's Application for Opdivo(R) (nivolumab) Plus Chemotherapy Combination for Classical Hodgkin Lymphoma	AQ
12-11	U.S. Food and Drug Administration (FDA) Grants Priority Review to Bristol Myers Squibb's Application for Opdivo® (nivolumab) Plus Chemotherapy Combination for Classical Hodgkin Lymphoma	BU
12-10	Bristol Myers Squibb Announces Dividend Increase	BU
12-08	Bristol Myers Squibb Advances Lymphoma Research with New Targeted Protein Degradation and Cell Therapy Data at ASH 2025	BU
12-05	Bristol Myers Squibb’s Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL)	BU
12-03	Bristol Myers Squibb Announces Continuation of ADEPT-2 Phase 3 Study in Psychosis Associated with Alzheimer's Disease	BU
12-01	Bristol Myers Squibb Data at ASH 2025 Showcase Potential of Hematology Pipeline and Build Momentum for Next Generation Portfolio	BU
11-26	Bristol Myers Squibb to Participate in Citi’s 2025 Global Healthcare Conference	BU
11-24	Bristol Myers Squibb Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Mantle Cell Lymphoma	BU
11-24	Bristol Myers Squibb to Host Hematology-Focused Investor Event	BU
11-18	Bristol Myers Squibb Announces Accepted Amounts and Pricing Terms of its Tender Offers	BU
11-18	Bristol Myers Squibb Announces Early Participation Results, Amendment and Early Settlement of Tender Offers	BU
11-14	Update on Phase 3 Librexia ACS Trial	BU
11-06	Bristol Myers Squibb Prices EUR5 Billion of Senior Unsecured Notes	AQ
11-05	Bristol Myers Squibb Prices €5 Billion of Senior Unsecured Notes	BU
11-03	Bristol Myers Squibb Showcases New Long-Term and Real-World Data From Cardiovascular Portfolio at the American Heart Association Scientific Sessions 2025	BU
11-03	Bristol Myers Squibb Announces Cash Tender Offers to Purchase Certain Notes	BU
30/10/25	Bristol Myers: Q3 Earnings Snapshot	AQ
30/10/25	Bristol Myers Squibb : Q3 2025 Results Presentation (with Appendix)	PU
30/10/25	Bristol Myers Squibb Reports Third Quarter Financial Results for 2025	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Filters

Headlines

Technical Analysis: Bristol-Myers Squibb hesitates at a critical juncture

August 28, 2025 at 08:51 am